| Market Capitalization (Millions $) |
15,775 |
| Shares
Outstanding (Millions) |
267 |
| Employees |
1,147 |
| Revenues (TTM) (Millions $) |
2,375 |
| Net Income (TTM) (Millions $) |
1,837 |
| Cash Flow (TTM) (Millions $) |
42 |
| Capital Exp. (TTM) (Millions $) |
7 |
Business Description
Exelixis Inc.
is a biopharmaceutical company headquartered in Alameda, California, United States.
The company was founded in 1994, and it develops and commercializes proprietary therapeutics for the treatment of cancer and other serious diseases.
Exelixis has a diverse pipeline of small molecule therapeutics that are designed to address various types of cancer.
Its lead product, cabozantinib, is an inhibitor of multiple tyrosine kinases, including MET, VEGF receptors, AXL, RET, and ROS1.
Cabozantinib targets cancer cells in multiple ways and has demonstrated significant clinical benefits across several indications, including renal cell carcinoma, hepatocellular carcinoma, and advanced prostate cancer.
Apart from cabozantinib, Exelixis also has several other product candidates in its pipeline, including XL092, which is currently in Phase 1 clinical trials for the treatment of solid tumors, and XL102, which is being developed for the treatment of hematologic malignancies.
Exelixis has partnerships with several leading pharmaceutical companies, including Bristol Myers Squibb, Roche, and Merck.
These collaborations are aimed at advancing the development and commercialization of its small molecule therapeutics in various markets around the world.
Overall, Exelixis is a leading player in the field of cancer therapeutics, with a strong focus on innovation, research, and development.
The company is committed to improving the lives of patients with cancer and other serious diseases, and it is well-positioned to continue its growth trajectory in the coming years.
Company Address: 1851 Harbor Bay Parkway Alameda, 94502 CA
Company Phone Number: 837-7000 Stock Exchange / Ticker: NASDAQ EXEL
|
1.11% 
100 %